Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Victoria Billero

Dermatology Boston, MA Medical Doctor

NPI 1568967479 CMS profile 5706347

800 Washington St, Boston, MA 02111

Open in the dashboard

General payments

$1,127

22 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Victoria Billero of Boston, MA is reported in the CMS Open Payments database as having received $1,127 across 22 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 36th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $29 1
2022 General $328 5
2021 General $541 11
2020 General $36 2
2019 General $192 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victoria Billero
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Victoria Billero were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Victoria Billero Dermatology median Middle half National median
2019 $192 $454 $129–$1,240 $163
2020 $36 $235 $81–$756 $114
2021 $541 $377 $108–$1,108 $132
2022 $328 $514 $143–$1,391 $149
2023 $29 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $451 11 payments
  2. Galderma Laboratories, L.P. $289 3 payments
  3. Allergan Inc. $150 1 payment
  4. Pfizer Inc. $133 3 payments
  5. Regeneron Healthcare Solutions, Inc. $63 3 payments
  6. Genzyme Corporation $40 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,127 22 payments
Products named General payments · program years 2019–2023
  1. SKYRIZI $383 8 payments
  2. ORACEA $269 2 payments
  3. AKLIEF $156 1 payment
  4. BOTOX COSMETIC $150 1 payment
  5. HUMIRA $144 6 payments
  6. SOOLANTRA $113 1 payment
  7. CIBINQO $92 1 payment
  8. DUPIXENT $43 2 payments
  9. EUCRISA $40 2 payments
  10. RINVOQ $29 1 payment
  11. Other $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

437

Median for Dermatology: 534

Drug cost

$171,545

Median for Dermatology: $67,151

Branded share of claims

15.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 29 $106,671
Dupixent Syringe Dupilumab Brand 15 $53,734
Fluorouracil Generic 36 $1,896
Clobetasol Propionate Generic 35 $1,640
Tretinoin Generic 19 $1,536
Ketoconazole Generic 89 $1,397
Tacrolimus Generic 13 $1,040
Betamethasone Dipropionate Generic 15 $986
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 22 $976
Triamcinolone Acetonide Generic 80 $811

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$50,329

Medicare's payments for the services billed

Medicare patients

357

Average age 73

Services billed

909

216 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 46%
Ischemic heart disease 25%
Diabetes 24%
Osteoporosis 23%
Chronic kidney disease 21%
Depression 20%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

22 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record